Replies to post #357220 on Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Agree, we need updates on everything.
Everything seems to be on hold or making very slow progress, which is what you get for our shoestring budget and lack of capital.

I was somehow expecting some interim analysis for efficacy, based on prior guidance, and was thinking the 50% number would be it. I guess that's not happening. We only got the interim safety analysis to permit increased dosing from 3 to 5 days (after 25%).

Maybe it was this 10/20/20 PR:

http://www.ipharminc.com/press-release/2020/10/2/innovation-pharmaceuticals-announces-pre-ind-meeting-request-granted-by-fda-for-the-study-of-brilacidin-for-the-treatment-of-covid-19

Target enrollment is 120 patients, with a planned interim analysis.

Guess this was interim safety, not efficacy.

I thought there was something else, but can't find it.